EP4041227A4 - A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers - Google Patents
A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers Download PDFInfo
- Publication number
- EP4041227A4 EP4041227A4 EP20886771.3A EP20886771A EP4041227A4 EP 4041227 A4 EP4041227 A4 EP 4041227A4 EP 20886771 A EP20886771 A EP 20886771A EP 4041227 A4 EP4041227 A4 EP 4041227A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nanotechnologic
- approach
- novel
- solid lipid
- lipid carriers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000969 carrier Substances 0.000 title 1
- 208000005017 glioblastoma Diseases 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR201917444 | 2019-11-11 | ||
TR2020/07578A TR202007578A2 (en) | 2019-11-11 | 2020-05-14 | A new nanotechnological approach with solid lipid carriers to treat glioblastoma |
PCT/TR2020/051062 WO2021096464A1 (en) | 2019-11-11 | 2020-11-09 | A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4041227A1 EP4041227A1 (en) | 2022-08-17 |
EP4041227A4 true EP4041227A4 (en) | 2023-08-02 |
Family
ID=75912135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20886771.3A Pending EP4041227A4 (en) | 2019-11-11 | 2020-11-09 | A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4041227A4 (en) |
WO (1) | WO2021096464A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114588277B (en) * | 2022-04-07 | 2023-04-25 | 江苏省苏北人民医院 | Construction method of polydopamine nano-particles loaded with temozolomide and Pep-1 |
WO2024074666A1 (en) * | 2022-10-06 | 2024-04-11 | Mireca Medicines Gmbh | Conjugates for neuroretinal drug delivery |
-
2020
- 2020-11-09 WO PCT/TR2020/051062 patent/WO2021096464A1/en unknown
- 2020-11-09 EP EP20886771.3A patent/EP4041227A4/en active Pending
Non-Patent Citations (7)
Title |
---|
ANUPRIYA ANAND ET AL: "Brain targeted delivery of anticancer drugs: prospective approach using solid lipid nanoparticles", IET NANOBIOTECHNOLOGY, THE INSTITUTION OF ENGINEERING AND TECHNOLOGY, MICHAEL FARADAY HOUSE, SIX HILLS WAY, STEVENAGE, HERTS. SG1 2AY, UK, vol. 13, no. 4, 17 April 2019 (2019-04-17), pages 353 - 362, XP006109058, ISSN: 1751-8741, DOI: 10.1049/IET-NBT.2018.5322 * |
DEVI REKHA ET AL: "Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis", ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 32, no. 10, 22 July 2015 (2015-07-22), pages 3137 - 3148, XP035537490, ISSN: 0724-8741, [retrieved on 20150722], DOI: 10.1007/S11095-015-1677-3 * |
DUWA RAMESH ET AL: "Polymeric and lipid-based drug delivery systems for treatment of glioblastoma multiforme", JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY, THE KOREAN SOCIETY OF INDUSTRIAL AND ENGINEERING CHEMISTRY, KOREA, vol. 79, 6 July 2019 (2019-07-06), pages 261 - 273, XP085824896, ISSN: 1226-086X, [retrieved on 20190706], DOI: 10.1016/J.JIEC.2019.06.050 * |
MIRANDA ANA ET AL: "Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 531, no. 1, 9 August 2017 (2017-08-09), pages 389 - 410, XP085171863, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2017.07.049 * |
See also references of WO2021096464A1 * |
SENAY HAMARAT SANLIER ET AL: "In Vivo Biodistribution of Temozolomide and Carmustine Loaded Targeted Solid Lipid Nanoparticle", 26 October 2019 (2019-10-26), pages 175, XP009536054, Retrieved from the Internet <URL:https://www.ebatcongress.org/dosyalar/belge/9360_EBAT%202019%20ABSTRACT%20BOOK.pdf> * |
VENISHETTY VINAY KUMAR ET AL: "β-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE, vol. 9, no. 3, 1 April 2013 (2013-04-01), AMSTERDAM, NL, pages 388 - 397, XP055823090, ISSN: 1549-9634, DOI: 10.1016/j.nano.2012.08.004 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021096464A1 (en) | 2021-05-20 |
EP4041227A1 (en) | 2022-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2818756B8 (en) | Conveyor belt having opposing ends to be connected for endlessing the conveyor belt. | |
EP3857529A4 (en) | A vehicle-initiated approach to joining a group | |
ZA201400705B (en) | A novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes | |
EP3004362A4 (en) | Recombinant microorganisms exhibiting increased flux through a fermentation pathway | |
EP2951466A4 (en) | Spacer for belt tensioner | |
EP4041227A4 (en) | A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers | |
EP3004781A4 (en) | Minigun with improved feeder sprocket and shaft | |
WO2013011368A9 (en) | Novel il-17r-ecd mutants | |
EP2761726A4 (en) | Homopolar motor-generator | |
EP3019429A4 (en) | Conveyor band drive system | |
EP3415612A4 (en) | Planktonic strain of chlorella vulgaris for the production of edible biomass | |
EP3046856A4 (en) | Conveyor chain support | |
EP2984018A4 (en) | Chain drive system with polygon compensation | |
EP4069214A4 (en) | Polyphosphazene drug carriers | |
GB202002083D0 (en) | Photodetectors | |
AU2018900763A0 (en) | Improvements in or relating to carriers | |
TWI858595B (en) | A band with a built-in curvable battery | |
AU2012905360A0 (en) | A book with wraparound portion | |
AU2011904982A0 (en) | Cellular structured product 2 | |
AU2011904289A0 (en) | Conveyor idler roller assembly | |
AU2011901273A0 (en) | The Marlon Plug to Powerpoint Process | |
AU2012101534A4 (en) | A compact luminaire | |
AU2012904837A0 (en) | The macwell 100 group | |
AU2011902934A0 (en) | The Bowlers Aid | |
AU2011904559A0 (en) | Ctshws500/2.7 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220510 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031418800 Ipc: A61K0047140000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230704 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20230629BHEP Ipc: A61K 31/17 20060101ALI20230629BHEP Ipc: A61K 31/4188 20060101ALI20230629BHEP Ipc: A61K 9/51 20060101ALI20230629BHEP Ipc: A61K 47/14 20170101AFI20230629BHEP |